PEMF for
Heel Spur

June 2026 · 9 min read · Clinical Protocol

What Is a Heel Spur?

A heel spur (calcaneal spur) is a bony osteophyte — a calcium deposit — that forms on the inferior surface of the calcaneus (heel bone) at the insertion point of the plantar fascia or Achilles tendon. It develops as a response to chronic traction stress: where the fascia or tendon pulls repeatedly on the periosteum, the body lays down extra bone, producing a hook-shaped bony projection that can extend up to 3–5 mm anteriorly.

A clinically important distinction: heel spurs and plantar fasciitis frequently co-occur but are not the same condition. Heel spurs are bony structural changes visible on X-ray; plantar fasciitis is inflammation of the fascial band itself. Approximately 50% of plantar fasciitis patients have a co-existing heel spur, but the spur alone is not the primary pain generator — the periosteal inflammation and fascial pathology surrounding it are. This distinction matters for treatment selection.

Heel spurs affect approximately 10% of the general population. In the Philippines, risk factors are amplified: high rates of flat-footedness (pes planus), prolonged standing in occupational contexts (retail, manufacturing, healthcare), widespread use of thin-soled footwear, and high BMI prevalence all contribute to elevated calcaneal stress loads. Conservative estimates suggest 4–6 million Filipinos are symptomatic at any given time.

Why Heel Spurs Cause Pain: The Periosteal Mechanism

The pain from a calcaneal spur arises from three converging biological processes:

1. Periosteal inflammation: The periosteum (the fibrous layer covering bone) at the spur site is chronically inflamed. Traction from the plantar fascia with every weight-bearing step perpetuates this inflammation, generating IL-1β, TNF-α, and prostaglandin E2 — the same cytokine cascade seen in other chronic musculoskeletal pain conditions.
2. Fascial thickening and fibrosis: Chronic overload causes the plantar fascia to thicken (normal ≤ 4.0 mm; pathological ≥ 4.5 mm as measured by ultrasound). Thickened, fibrotic fascia has impaired viscoelasticity and poor tissue perfusion, perpetuating the inflammatory state.
3. Nerve entrapment: The bony spur can compress the calcaneal branch of the posterior tibial nerve or the medial calcaneal branches, producing a neuropathic component to the pain — burning, tingling, and pain at night (not just weight-bearing). This nerve compression does not resolve with orthotics or anti-inflammatory medications alone.

How PEMF Works for Heel Spurs

PEMF addresses all three components of heel spur pathology through distinct but complementary mechanisms:

1. Anti-Inflammatory Action

Pulsed electromagnetic fields suppress IL-1β, TNF-α, and COX-2 expression in periosteal and fascial cells, reducing the inflammatory cytokine cascade without systemic side effects. This directly addresses the periosteal inflammation that drives heel spur pain. Unlike corticosteroid injection, PEMF does not risk plantar fascia rupture with repeated application.

2. Bone Remodeling Regulation

PEMF modulates the OPG/RANKL ratio — the key regulatory balance between osteoblast-driven bone formation and osteoclast-driven bone resorption. By upregulating OPG (osteoprotegerin) and downregulating RANKL, PEMF favors controlled bone remodeling over osteophytic overgrowth. This is laboratory and bone-healing data, not a heel-spur outcome — see the evidence section below.

3. Fascial Tissue Healing

PEMF upregulates proteoglycan synthesis (+42% vs. sham; PMC3518856) and stimulates collagen fiber reorganization in connective tissue. The plantar fascia, chronically thickened and disorganized in heel spur patients, responds to PEMF with improved collagen alignment and reduced fibrotic changes — restoring normal viscoelastic function. Ultrasound-measured fascia thinning has been reported in an uncontrolled PEMF case series (see below).

Clinical Evidence

Two studies carry the evidence here, and they are not of the same strength — the difference matters more than the numbers themselves. Results:

• Randomized, double-blind, placebo-controlled trial (n=70) of a wearable PRFE device worn overnight: 40% reduction in first-step morning pain at day 7 vs. 7% on placebo (p=0.03). Evening pain fell 30% vs. 19% on placebo — not statistically significant. Brook et al., J Foot Ankle Surg 2012, PMID 22297104
• 12-week case series using a PEMF device alongside stretching: mean plantar fascia thickness −34% on ultrasound, FADI +46%. Bromley et al., J Am Podiatr Med Assoc 2025, PMID 40378087 — no control group and no randomization, and the widely quoted "34% vs. 16% for steroid injection" comparison uses historical controls from other studies, not a head-to-head arm
• Systematic review 2026 (4 RCTs, n=243) of foot and ankle soft-tissue injury: significant pain reduction in 3 of 4 trials; significant functional improvement in only 1 of 3. PMID 41716305

What none of this shows is that PEMF shrinks the spur. PEMF acts on soft tissue, not on existing bone. In most patients the calcaneal spur is not the pain generator at all: it is found in asymptomatic feet, and many symptomatic patients have no spur on X-ray. The treatment target is the plantar fascia, and the outcome to measure is pain and function — not a repeat X-ray.

A separate meta-analysis of PEMF in bone healing (Bioelectromagnetics 2020, PMID 32495506) reports effects on bone healing in fracture populations. ⚠️ That is a different clinical question from heel spur management, and extrapolating it to osteophyte regulation at the calcaneus would be an inference rather than a finding — so this page does not make it.

Treatment Protocol

• Patient positioning: Supine or seated with foot slightly elevated
• Coil placement: Sole applicator or flat coil applied to plantar surface of heel; ensure field coverage extends to calcaneal tuberosity and plantar fascia origin
• Frequency: 8–25 Hz (lower range for neuropathic/nerve entrapment component; higher range for periosteal inflammation)
• Intensity: 8–15 mT
• Session duration: 30 minutes
• Treatment frequency: 3 sessions per week for the first 4 weeks; 2 sessions per week thereafter
• Course length: 12 sessions standard; extend to 18 if fascia thickness remains above 4.2 mm at ultrasound reassessment
• Expected timeline: Morning pain typically improves by session 4–6; reassess fascia thickness by ultrasound at 8–12 weeks where available
• Combination: PEMF leads, together with the insoles, stretching and exercises the patient already does (the insoles unload the insertion site during the course)
• Philippine pricing: ₱1,500–₱2,500 per session

PEMF vs. Standard Heel Spur Treatments

Philippine Market Context

Heel spur represents one of the highest-volume single-indication opportunities in Philippine outpatient clinics. The combination of occupational risk factors — prolonged standing in retail, service, and manufacturing sectors; widespread jeepney/tricycle commuting with impact-transmitted calcaneal stress; and thin-soled footwear norms — creates a patient population several times larger relative to population than in temperate-climate markets.

The typical Filipino heel spur patient has been managing with over-the-counter ibuprofen and improvised orthotics for months to years. The entry barrier to PEMF is low: no blood tests, no surgery, no bed rest. The treatment narrative is compelling — ultrasound-confirmed structural improvement is a tangible, documentable outcome that drives patient retention and referral.

70+ Israeli clinics (population: 9M) routinely include heel spur in their PEMF indication mix, treating 3–6 heel spur patients per machine per week. The Philippine foot pain market is proportionally larger and significantly underserved.

Contraindications

Standard PEMF contraindications apply: active implanted pacemaker or neurostimulator, pregnancy, active epilepsy, active malignancy at the treatment site. Metallic implants in the foot (e.g., subtalar fusion hardware) require review by the attending physician — stainless steel implants may require repositioning of the coil; titanium implants do not interact with PEMF fields and are generally safe.

Frequently Asked Questions

Does PEMF dissolve the heel spur itself?

No. PEMF acts on soft tissue, not on existing bone, and no study shows that it shrinks a spur. What it works on is the inflamed plantar fascia and the sensitised tissue around the spur — which, in most patients, is where the pain comes from; the spur itself often is not. Very large spurs causing mechanical nerve impingement may need ESWT or a surgical consultation.

How does PEMF compare to shockwave therapy for heel spur?

Extracorporeal shockwave therapy (ESWT) produces its effect through controlled tissue microtrauma, stimulating a healing response. It is effective (70%+ response rate) but involves significant procedural pain. PEMF acts through anti-inflammatory and cellular signaling pathways without tissue trauma — it is better tolerated and more appropriate for patients with sensitivity or comorbidities. For severe, entrenched spurs unresponsive to PEMF, sequential PEMF + ESWT protocols are used in Israeli clinics.

Does PEMF replace insoles and physiotherapy?

No — the pulses don't come instead of the insoles and physiotherapy; they are what lets you do the exercises and keep at them. In a double-blind, multi-centre trial of 70 patients with plantar fasciitis (Brook et al., J Foot Ankle Surg 2012, PMID 22297104), first-step morning pain fell 40% after 7 nights with a wearable pulsed-electromagnetic device, versus 7% with a sham device.

How many sessions before patients notice improvement?

In the wearable trial (worn overnight), first-step morning pain had fallen 40% by day 7. With in-clinic sessions at 3x/week, patients typically report less morning pain by session 4–6. Patients should be counseled that the first 3–4 sessions are establishing the anti-inflammatory base before subjective improvement becomes consistent.